Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 OCF Margin % is -25.50% as of Dec. 2025. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, CF PharmTech ranks worse than 87.72% on this metric.
The historical data trend for CF PharmTech's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech OCF Margin % Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
OCF Margin %
13.02
20.90
15.87
-25.50
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
OCF Margin %
13.02
20.90
15.87
-25.50
HKSE:02652 vs ZTS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's OCF Margin % distribution charts can be found below:
* The bar in red indicates where CF PharmTech's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a OCF Margin % of -25.50% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CF PharmTech and its competitors. According to the industry distribution chart, CF PharmTech ranks #843 out of 961 companies in the Drug Manufacturers industry, placing it in the top 87.7%.
Is CF PharmTech's OCF Margin % too high?
CF PharmTech's current OCF Margin % is -25.50%. Based on the distribution chart, CF PharmTech ranks #843 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #843 out of 961 companies for OCF Margin %. This places CF PharmTech in the lower half of its industry. The industry median OCF Margin % is 9.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.77, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current OCF Margin % is -25.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current OCF Margin % of -25.50%. The current OCF Margin % is -25.50%. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current OCF Margin % is -25.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
